Attached files
| file | filename |
|---|---|
| EX-99.1 - Universal Resources | v215361_ex99-1.htm |
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: March 21, 2011
GLOBAL IMMUNE TECHNOLOGIES, INC.
(Exact Name of registrant as specified in its Charter)
|
Wyoming
|
0-30520
|
98-05327255
|
|
(State of Incorporation)
|
Commission File No.
|
(IRS Employer
|
|
Identification No.)
|
|
2809 Great Northern Loop, Suite 100, Missoula, MT
|
59808-1749
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, ( 406 ) 558 - 4947
(Registrant’s former name and address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions below:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240-14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
|
Item 9.01
Exhibit 99.1 - Press Release dated March 21, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Global Immune Technologies, Inc.
Dated: March 21, 2011
By: Donald L. Perks
Title: Director & President